Data from POTOMAC support durvalumab plus BCG and induction and maintenance therapy as a new treatment option in BCG-naive, high-risk NMIBC.
Paige Britt
Advertisement
Articles by Paige Britt
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
2
Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC
3
Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma
4
Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC
5
